Provided by Tiger Fintech (Singapore) Pte. Ltd.

NeuroPace Inc.

11.69
-0.2900-2.42%
Pre-market: 11.68-0.0100-0.09%07:54 EDT
Volume:108.58K
Turnover:1.27M
Market Cap:380.63M
PE:-12.55
High:11.86
Open:11.73
Low:11.26
Close:11.98
Loading ...

NeuroPace’s Strong Market Position and Growth Potential Justify Buy Rating Amid Tariff Stability

TIPRANKS
·
16 Apr

BRIEF-Neuropace Provides Update On Tariff Status

Reuters
·
15 Apr

NeuroPace Reports 'Minimal impact' From Trump Tariffs

MT Newswires Live
·
15 Apr

NeuroPace Expects Minimal Impact from Trade Tariffs

TIPRANKS
·
15 Apr

NeuroPace expects minimal impact from tariffs

TIPRANKS
·
15 Apr

Neuropace Inc - Expects Minimal Impact From Tariffs

THOMSON REUTERS
·
15 Apr

Neuropace Provides Update on Tariff Status

THOMSON REUTERS
·
15 Apr

Neuropace Inc - Reiterates Gross Margin Guidance for 2025

THOMSON REUTERS
·
15 Apr

NeuroPace Provides Update on Tariff Status

GlobeNewswire
·
15 Apr

Neuropace Announces Data From a Long-Term Post-Approval Study of the Rns System in Focal Epilepsy at the 2025 Aan Annual Meeting

THOMSON REUTERS
·
08 Apr

NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting

GlobeNewswire
·
08 Apr

NeuroPace (NPCE) Receives a Buy from Lake Street

TIPRANKS
·
03 Apr

Neuropace Announces Upcoming Oral Presentation of Data From the Long-Term Post-Approval Study of the Rns System at the 2025 Aan Annual Meeting

THOMSON REUTERS
·
03 Apr

NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

GlobeNewswire
·
03 Apr

NeuroPace to End Stereo EEG Distribution Accord; 2025 Revenue Guidance Affirmed

MT Newswires Live
·
03 Apr

NeuroPace Shifts Focus to Core RNS System

TIPRANKS
·
03 Apr

BRIEF-Neuropace Inc Maintaining 2025 Revenue Guidance

Reuters
·
03 Apr

NeuroPace to terminate distribution relationship for Seeg products

TIPRANKS
·
03 Apr

Neuropace Inc: No Change to Long-Range Plan Expectations of Cash Flow Breakeven by End of 2027

THOMSON REUTERS
·
03 Apr

Neuropace Inc: Maintaining 2025 Revenue Guidance

THOMSON REUTERS
·
03 Apr